Press releases

8
Apr 2022
20:30 E.S.T.

Cellectis Presents Preclinical Data from its First Allogeneic Dual CAR T-cell Product Candidate UCART20x22 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Read more
11
Mar 2022
18:15 E.S.T.

Cellectis to Participate in Two Upcoming Investor Conferences in March

Read more
3
Mar 2022
18:46 E.S.T.

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 Financial Results

Read more
24
Feb 2022
18:13 E.S.T.

Cellectis to Hold Fourth Quarter 2021 Earnings Call on Friday March 4, 2022 at 8:00AM EST

Read more
18
Feb 2022
20:22 E.S.T.

Calyxt Announces Pricing of Offering of Common Stock and Warrants and Updates Business and Risk Factor Disclosure

Read more
10
Feb 2022
21:44 E.S.T.

Cellectis Appoints Bing Wang, PhD, MBA as Chief Financial Officer

Read more
10
Jan 2022
21:30 E.S.T.

Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials

Read more
4
Jan 2022
19:37 E.S.T.

Cellectis Provides Business Objectives for 2022 and Updates its Corporate Presentation

Read more
11
Dec 2021
15:11 E.S.T.

Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting

Read more
18
Nov 2021
18:44 E.S.T.

Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboration in China

Read more

Press contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US